Mapatumumab

DB18945InvestigationalProtein Based Therapies

Mapatumumab is under investigation in clinical trial NCT00094848 (Study of TRM-1 (TRAIL-R1 Monoclonal Antibody) in Subjects With Relapsed or Refractory Non-hodgkin's Lymphoma (NHL)).

Mechanism: Pharmacologically active on Tumor necrosis factor receptor superfamily member 10A
Curator reviewed
Also known as: Immunoglobulin g1, anti-(human cytokine receptor dr4 (death receceptor 4)) (human monoclonal trm-1 heavy chain), disulfide with human monoclonal trm-1 .lambda.-chain, dimer · Immunoglobulin g1, anti-(human cytokine receptor dr4 (death receceptor 4)) (human monoclonal trm-1 heavy chain), disulphide with human monoclonal trm-1 .lambda.-chain, dimer · Immunoglobulin g1, anti-(human cytokine receptor dr4 (death receptor 4)) (human monoclonal trm-1 heavy chain), disulfide with human monoclonal trm-1 .lambda.-chain, dimer · Immunoglobulin g1, anti-(human trail-r1) (human monoclonal trm-1 heavy chain), disulfide with human monoclonal trm-1 .lambda.-chain, dimer · Mab human (igg1) anti o00220 (tr10a_human) (hgs1012)
Code names: HGS-1012 · HGS-ETR1 · TRM-1 · TRM-1 HGS-ETR1

Resolves to

Compound

UNIIWZ1025JPGRCAS658052-09-6

Targets

O00220TNFRSF10A

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

5Clinical trialsPhase, status and sponsor resolved per trial

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with Mapatumumab, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account